Kurt T Barnhart1, Wensheng Guo, Mark S Cary, Christopher B Morse, Karine Chung, Peter Takacs, Suneeta Senapati, Mary D Sammel. 1. Departments of Obstetrics and Gynecology and Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; the Department of Obstetrics and Gynecology, University of Southern California Keck School of Medicine, Los Angeles, California; and the Department of Obstetrics and Gynecology, University of Miami School of Medicine, Miami, Florida.
Abstract
OBJECTIVE: To assess whether variation in serum human chorionic gonadotropin (hCG) measures, used to assess early gestation viability, are associated with differences in clinical presentation and patient factors. METHOD: This retrospective cohort study included 285 women with first-trimester pain and bleeding and a pregnancy of unknown location for whom a normal intrauterine pregnancy was ultimately confirmed. Serial samples were collected at three U.S. sites and hCG changes were analyzed for differences by race, ethnicity, and clinical factors. A nonlinear, mixed-effects regression model was used assuming a random subject shift in the time axis. RESULTS: The hCG rise in symptomatic women with ongoing intrauterine pregnancy differs by patient factors and level at presentation. The 2-day minimum (first percentile) rise in hCG was faster when presenting hCG values were low and slower when presenting hCG value was high. African American women had a faster hCG rise (P<.001) compared with non-African American women. Variation in hCG curves was associated with prior miscarriage (P=.014), presentation of bleeding (P<.001), and pain (P=.002). For initial hCG values of less than 1,500, 1,500-3,000 and greater than 3,000 milli-international units/mL, the predicted 2-day minimal (first percentile) rise was 49%, 40%, and 33%, respectively. CONCLUSION: The rise of hCG levels in women with viable intrauterine pregnancies and symptoms of potential pregnancy failure varies significantly by initial value. Changes in hCG rise related to race should not affect clinical care. To limit interruption of a potential desired intrauterine pregnancy, a more conservative "cutoff" (slower rise) is needed when hCG values are high. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00194168.
OBJECTIVE: To assess whether variation in serum humanchorionic gonadotropin (hCG) measures, used to assess early gestation viability, are associated with differences in clinical presentation and patient factors. METHOD: This retrospective cohort study included 285 women with first-trimester pain and bleeding and a pregnancy of unknown location for whom a normal intrauterine pregnancy was ultimately confirmed. Serial samples were collected at three U.S. sites and hCG changes were analyzed for differences by race, ethnicity, and clinical factors. A nonlinear, mixed-effects regression model was used assuming a random subject shift in the time axis. RESULTS: The hCG rise in symptomatic women with ongoing intrauterine pregnancy differs by patient factors and level at presentation. The 2-day minimum (first percentile) rise in hCG was faster when presenting hCG values were low and slower when presenting hCG value was high. African American women had a faster hCG rise (P<.001) compared with non-African American women. Variation in hCG curves was associated with prior miscarriage (P=.014), presentation of bleeding (P<.001), and pain (P=.002). For initial hCG values of less than 1,500, 1,500-3,000 and greater than 3,000 milli-international units/mL, the predicted 2-day minimal (first percentile) rise was 49%, 40%, and 33%, respectively. CONCLUSION: The rise of hCG levels in women with viable intrauterine pregnancies and symptoms of potential pregnancy failure varies significantly by initial value. Changes in hCG rise related to race should not affect clinical care. To limit interruption of a potential desired intrauterine pregnancy, a more conservative "cutoff" (slower rise) is needed when hCG values are high. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT00194168.
Authors: Beata E Seeber; Mary D Sammel; Wensheng Guo; Lan Zhou; Amy Hummel; Kurt T Barnhart Journal: Fertil Steril Date: 2006-06-06 Impact factor: 7.329
Authors: Bruno C Casanova; Mary D Sammel; Jesse Chittams; Kelly Timbers; Jennifer L Kulp; Kurt T Barnhart Journal: J Womens Health (Larchmt) Date: 2009-02 Impact factor: 2.681
Authors: Peter M Doubilet; Carol B Benson; Tom Bourne; Michael Blaivas; Kurt T Barnhart; Beryl R Benacerraf; Douglas L Brown; Roy A Filly; J Christian Fox; Steven R Goldstein; John L Kendall; Edward A Lyons; Misty Blanchette Porter; Dolores H Pretorius; Ilan E Timor-Tritsch Journal: N Engl J Med Date: 2013-10-10 Impact factor: 91.245
Authors: Christopher B Morse; Mary D Sammel; Alka Shaunik; Lynne Allen-Taylor; Nicole L Oberfoell; Peter Takacs; Karine Chung; Kurt T Barnhart Journal: Fertil Steril Date: 2012-01 Impact factor: 7.329
Authors: George Condous; Ben Van Calster; Emma Kirk; Zara Haider; Dirk Timmerman; Sabine Van Huffel; Tom Bourne Journal: Fertil Steril Date: 2007-05-17 Impact factor: 7.329
Authors: Kurt T Barnhart; Bruno Casanova; Mary D Sammel; Kelly Timbers; Karine Chung; J L Kulp Journal: Obstet Gynecol Date: 2008-12 Impact factor: 7.661
Authors: Christopher B Morse; Kurt T Barnhart; Suneeta Senapati; Mary D Sammel; Erica C Prochaska; Anuja Dokras; Charalampos Chatzicharalampous; Christos Coutifaris Journal: Fertil Steril Date: 2016-01-23 Impact factor: 7.329
Authors: A Freis; J Schlegel; R J Kuon; A Doster; J Jauckus; T Strowitzki; A Germeyer Journal: Reprod Biol Endocrinol Date: 2017-11-02 Impact factor: 5.211
Authors: Hayley Richardson; Charikleia Kalliora; Monica Mainigi; Christos Coutifaris; Mary D Sammel; Suneeta Senapati Journal: F S Rep Date: 2021-12-31